SLC5A2 and type 2 diabetes mellitus: Although focusing mainly on cardiovascular outcomes, a VERTIS trial analysis reported that the SGLT2 inhibitor ertugliflozin significantly reduced an exploratory composite kidney endpoint, including a sustained 40% eGFR decline, dialysis/transplant, or renal death (HR 0.66, CI 0.50–0.88) in patients with T2D and atherosclerotic cardiovascular disease [52].